Apolipoprotein C3 as A Paradoxical Inhibitor of Platelet Aggregation and Thrombosis – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Waltraud C. Schrottmaier et al, adding:
”Elevated Levels of Apolipoprotein C3 Impair Platelet Function and Reduce Thrombosis
ApoC3, a known cardiovascular risk factor, paradoxically acts as a lipoprotein-derived inhibitor of platelet aggregation and thrombosis by modulating AKT and VASP signaling and disrupting actin cytoskeleton remodeling, potentially counterbalancing its proatherogenic effects in hyperlipidemia.”
Title: Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis
Authors: Waltraud C. Schrottmaier, Julia B. Kral-Pointner, Marion Mussbacher, Manuel Salzmann, Bernhard Hochreiter, Anita Pirabe, Theresa Reiter, Sigrun Badrnya, Johannes A. Schmid, Ivo Volf, Alice Assinger
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 25, 2026, 15:56Wolfgang Miesbach: Building the Future of Gene Therapy – From Centre Readiness to Long-Term Patient Care
-
Jun 25, 2026, 15:46Amber Yates: Making a Meaningful Difference for People Living with Sickle Cell Disease
-
Jun 25, 2026, 15:43Nancy Cavey: Navigating Disability Benefits for Patients with Immune Thrombocytopenia
-
Jun 25, 2026, 15:28Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy
-
Jun 25, 2026, 15:23Jonas Kingo: ISTH 2026 in Paris Brings the Global Hemostasis Community Together
-
Jun 25, 2026, 15:21Balancing Therapeutic Progress and Emergency Preparedness in Hemophilia – CRH French Reference Center for Hemophilia Lyon
-
Jun 25, 2026, 15:06Ifeanyichukwu Ifechidere: What If One of the Biggest Myth Fact About APS is Hidden in its Name?
-
Jun 25, 2026, 15:05Gopal Patidar: Advancing Haemovigilance and Global Collaboration at ISBT 2026
-
Jun 25, 2026, 14:52Violeta Jardin: Measuring Antifibrinolytic Effect to Improve Tranexamic Acid Safety